Thymosin

Sepsis Drug Pipeline Research Report 2024: Insights from 30 Companies and 35 Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Pharmaceutical, Health, Clinical Trials, Therapy, Acquisition, Blood pressure, HBV, HCV, Hepatitis B virus, Heparin, CRISPR, Infection, Escherichia coli, Melanoma, News, Cancer, Liver cancer, Discovery, Cell, Vaccine, Intensive care medicine, Adrenomedullin, ADM, COVID, Fungal infection, Patient, Protein, Clinical trial, Survival, Endothelium, NDA, Histone, Thymosin

This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.
  • A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines.
  • This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.

Sepsis - Pipeline Insight, 2022: Innovations from SciClone, Sanofi, BioAegis & More Set to Transform Sepsis Treatment - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 8, 2023
Health, Clinical Trials, Route, Protein, Cholesterol, COVID, Intensive care medicine, Infection, III, Therapy, Vaccine, Pneumonia, Cell, News, HCV, Clinical trial, Discovery, Bacterial pneumonia, Bacteria, Artery, Administration, Liver cancer, Patient, PCSK9, Risk, Heparin, Thymosin, Survival, Route of administration, Immunotherapy, Melanoma, Alirocumab, HBV, Cancer, Inflammation, LDL, Histone, Fungal infection, Hepatitis B virus, Pharmaceutical industry, Medical device, Sepsis

This "Sepsis- Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Sepsis pipeline landscape.

Key Points: 
  • This "Sepsis- Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Sepsis pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D.
  • This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • Sepsis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy

Retrieved on: 
Tuesday, January 31, 2023
Survival, Heart, Myocardial injury after non-cardiac surgery, OTCQB, Liver, Ageing, Brain, Molecular medicine, Gene expression, Animal, Biochemistry, George Washington University School of Medicine & Health Sciences, Lung, Kidney, Thymosin, Regeneration, George Washington University School of Engineering and Applied Science, Research, Pharmaceutical industry

Using the heart as a model experimental system, a research team from Hungary and the United States summarized and expanded upon their previous results regarding Thymosin beta 4 (Tβ4) to support their anti-aging hypothesis.

Key Points: 
  • Using the heart as a model experimental system, a research team from Hungary and the United States summarized and expanded upon their previous results regarding Thymosin beta 4 (Tβ4) to support their anti-aging hypothesis.
  • Their research proved that Tβ4 is expressed in the developing heart and promotes cardiac cell migration and survival.
  • Finally, the researchers discovered Tβ4 is capable of epicardial progenitor activation, and revealed the effect is independent of hypoxic injury.
  • The publication is entitled, Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies; Int Immunopharmacol.

Researchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsis

Retrieved on: 
Wednesday, October 6, 2021
Acute kidney injury, Mortality, Patent, Clinical trial, Systemic inflammatory response syndrome, OTCQB, Cell death, Annual report, AKI, Diagnosis, Patient, Risk, Security (finance), Inflammation, Private Securities Litigation Reform Act, Septic shock, Thymosin, U.S. Securities and Exchange Commission, George Washington University School of Medicine & Health Sciences, COVID-19, Association, Sepsis, Biochemistry, Form 10-K, Death, Company, Molecular medicine, Research, ICU, T4, Infection, Forward-looking statement, The Department, SEC, Regeneration, Pharmaceutical industry

According to the study, 92 patients developed acute kidney injury (AKI), 29 patients died within 7 days, and 53 patients died within 28 days.

Key Points: 
  • According to the study, 92 patients developed acute kidney injury (AKI), 29 patients died within 7 days, and 53 patients died within 28 days.
  • After statistical analyses, the research team found that lower T4 levels correlated with poorer prognosis and increased mortality risk in patients with sepsis.
  • The study, Association between Thymosin beta-4, acute kidney injury, and mortality in patients with sepsis: An observational cohort study, was published by Zhang et.
  • In the ICU, almost 50% of sepsis patients will develop AKI, thereby increasing the mortality rate by 3050%.

New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease

Retrieved on: 
Tuesday, October 5, 2021
Patent, Clinical trial, OTCQB, Annual report, Risk, Memory, Security (finance), Alzheimer's disease, Private Securities Litigation Reform Act, Depression, U.S. Securities and Exchange Commission, Cognitive behavioral therapy, George Washington University School of Engineering and Applied Science, Thymosin, Biochemistry, Disease, Form 10-K, Lists of diseases, Company, Government budget balance, George Washington University School of Medicine & Health Sciences, Drug combination, Journal, NF, Research, Human, Molecular medicine, Journal of Neuroinflammation, Learning, Forward-looking statement, Anxiety, SEC, Regeneration, Department, Pharmaceutical industry

The research team also observed that over-expression of T4 improved neuronal function and cognitive behavior performance and displayed anti-depressant-like effects.

Key Points: 
  • The research team also observed that over-expression of T4 improved neuronal function and cognitive behavior performance and displayed anti-depressant-like effects.
  • In the study, T4 down regulated certain known inflammatory pathways, while other drug combinations did not, in particular NF-B signaling.
  • RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T4) and its constituent fragments, for tissue and organ protection, repair, and regeneration.
  • Forward-looking statements in this press release include but are not limited to statements from us or within research published by third parties.

RegeneRx Issues Letter To Stockholders

Retrieved on: 
Thursday, July 22, 2021
Life sciences, Biotechnology, Articles, Beta thymosins, OTC Markets Group, Thymosin, Biopharmaceutical, Food and Drug Administration, Regeneration

ROCKVILLE, Md., July 22, 2021 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, has issued a Letter to Stockholders updating its recent financing, the FDA regulatory process for RGN-259, and its 12-month operating strategy.

Key Points: 
  • ROCKVILLE, Md., July 22, 2021 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, has issued a Letter to Stockholders updating its recent financing, the FDA regulatory process for RGN-259, and its 12-month operating strategy.
  • The Letter may be viewed at RegeneRx's homepage: www.regenerx.com .
  • RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T4) and its constituent fragments, for tissue and organ protection, repair, and regeneration.
  • Any statements in this shareholder letter that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995.

RegeneRx Issues Update on ARISE-3 Trial

Retrieved on: 
Monday, March 22, 2021
Beta thymosins, Thymosin, Peptide, Guarantee, Forward-looking statement, Articles, Thymosin beta-4

RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T4) and its constituent fragments, for tissue and organ protection, repair, and regeneration.

Key Points: 
  • RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T4) and its constituent fragments, for tissue and organ protection, repair, and regeneration.
  • Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995.
  • Moreover, there is no guarantee any clinical trial will be successful or confirm previous clinical results.
  • The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

RegeneRx Issues Year End Letter To Stockholders

Retrieved on: 
Monday, December 21, 2020
Life sciences, Biology, Articles, Beta thymosins, Healing, OTC Markets Group, Thymosin, Biopharmaceutical, Regeneration

ROCKVILLE, Md., Dec. 21, 2020 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, issued a year-end Letter to Stockholders.

Key Points: 
  • ROCKVILLE, Md., Dec. 21, 2020 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, issued a year-end Letter to Stockholders.
  • The Letter may be viewed at RegeneRx's homepage: www.regenerx.com .
  • RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T4) and its constituent fragments, for tissue and organ protection, repair, and regeneration.
  • Any statements in this shareholder letter that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995.

RegeneRx Advisory on Reclassification of Thymosin Beta 4 from Drug to Biologic

Retrieved on: 
Wednesday, May 27, 2020
Health, Articles, Life sciences, Pharmaceutical industry, Beta thymosins, Biotechnology, Thymosin, Biopharmaceutical, Food and Drug Administration, Clinical trial, Thymosin beta-4

ROCKVILLE, Md., May 27, 2020 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the FDA's reclassification of Thymosin beta 4 (T4) from a drug to a biologic, http://www.regenerx.com/2020-05-27-Reclassification-of-Thymosin-Beta-4-f... .

Key Points: 
  • ROCKVILLE, Md., May 27, 2020 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the FDA's reclassification of Thymosin beta 4 (T4) from a drug to a biologic, http://www.regenerx.com/2020-05-27-Reclassification-of-Thymosin-Beta-4-f... .
  • RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T4) and its constituent fragments, for tissue and organ protection, repair, and regeneration.
  • Moreover, there is no guarantee any clinical trial will be successful or confirm previous clinical results.
  • The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

RegeneRx Issues Advisory on ARISE-3 Dry Eye Trial

Retrieved on: 
Monday, April 20, 2020
Health, Beta thymosins, Clinical trial, Thymosin, Regeneration, Pharmacology, Thymosin beta-4

ROCKVILLE, Md., April 20, 2020 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration issued an advisory on its dry eye syndrome Phase 3 clinical trial.

Key Points: 
  • ROCKVILLE, Md., April 20, 2020 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration issued an advisory on its dry eye syndrome Phase 3 clinical trial.
  • To access the advisory, go to the following link: http://www.regenerx.com/2020-04-20-April-20-2020-Advisory-Update-on-ARIS... .
  • RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T4) and its constituent fragments, for tissue and organ protection, repair and regeneration.
  • Moreover, there is no guarantee any clinical trial will be successful or confirm previous clinical results.